1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Omicron leaves Germany on brink of recession as growth dips

01/14/2022 | 07:06am EDT

FRANKFURT, Germany (AP) — The risk of recession is looming for Germany after Europe’s biggest economy shrank at the end of 2021 and as it faces a bumpy start to this year, with the rapid spread of COVID-19's omicron variant deterring people from shopping and travel and supply bottlenecks holding back manufacturers.

Output in Germany fell by between 0.5% and 1% in the fourth quarter, the state statistics agency Destatis said Friday. Forecasts are also shaky for the first three months of 2022, and two straight quarters of falling output would leave Germany in recession, according to one commonly used definition.

Germany helps set the pace for the entire eurozone, the 19 European Union countries that use the euro currency and one of the world's largest economies. Many German companies have suppliers or factories in other European countries, so Germany's business activity can boost growth for its neighbors.

For all of last year, the German economy grew 2.7%, rebounding from a plunge of 4.6% in 2020 when pandemic lockdowns were at their most severe.

One company — vaccine maker BioNTech, which is based in Mainz — contributed a full 0.5% to 2021 economic output from licensing income on the COVID-19 vaccine it developed with Pfizer.

“It is extremely unusual that one company lifts GDP so much," said economist Nils Jannsen at the Kiel Institute for the World Economy, referring to gross domestic product, the common measure of a country’s economic output.

He said the jump was due to the complete absence of BioNTech licensing income the year before.

German growth remains below its pre-pandemic level and lags the estimated eurozone figure of 5% as performance was less robust than several other major economies such as France, Spain and Italy.

Germany's manufacturing and export-heavy economy was hit hard by global difficulties in getting parts and raw materials, leaving companies unable to sell goods despite strong demand from customers as the economy roared back from the depths of the pandemic, said Carsten Brzeski, global head of macro at ING bank.

“No other eurozone country suffered as much as the German economy amid a series of supply chain frictions,” he wrote in a research email. “Industrial production has basically stagnated since spring last year, despite richly filled order books and very low inventories.”

Complete statistics for the fourth quarter will be released on Jan. 28. A lag in gathering numbers at the end of the year means the figure for the full year is available before the one for the last three months of the year.

Copyright 2022 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission., source Associated Press News

All news about BIONTECH SE
05/17Pfizer-BioNTech COVID-19 Vaccine Booster Approved for Children 5 to 11 Years Old in US
MT
05/17UBS Adjusts BioNTech Price Target to $168 From $170, Maintains Neutral Rating
MT
05/17Pfizer, BioNTech Receive US Approval for COVID-19 Jab Booster Dose for Children
MT
05/17Pfizer Gets FDA Emergency Use Authorization for COVID-19 Vaccine as Booster Dose in Chi..
MT
05/17FDA Expands Authorization of Pfizer Covid Booster to Kids 5 to 11
DJ
05/17PRESS RELEASE : Coronavirus (COVID-19) Update: FDA Expands Eligibility for Pfizer-BioNTech..
DJ
05/16European ADRs Move Higher in Monday Trading
MT
05/16WALL STREET STOCK EXCHANGE : China added to the list of investors' fears
05/16Pfizer and BioNTech Provide Update on COVID-19 Vaccine Supply Agreement with European C..
AQ
05/15Pfizer, BioNTech Agree To Move Delivery Schedules For COVID-19 Vaccines In EU
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2022 16 795 M 17 691 M 17 691 M
Net income 2022 8 929 M 9 404 M 9 404 M
Net cash 2022 16 669 M 17 557 M 17 557 M
P/E ratio 2022 4,40x
Yield 2022 -
Capitalization 36 869 M 38 834 M 38 834 M
EV / Sales 2022 1,20x
EV / Sales 2023 0,98x
Nbr of Employees 3 082
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 151,71 €
Average target price 225,86 €
Spread / Average Target 48,9%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE-38.01%38 834
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-16.20%42 682
GENMAB A/S-20.15%19 472